Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to Anti-HBs seroconversion in patients with chronic hepatitis B

Authors

  • Marie-Anne Loriot,

    1. Service d'Hépatologie and Unité de Recherches de Physiopathologie Hépatique (INSERM), Hǒpital Beaujon, 92118 Clichy, France
    Search for more papers by this author
  • Patrick Marcellin M.D.,

    Corresponding author
    1. Service d'Hépatologie and Unité de Recherches de Physiopathologie Hépatique (INSERM), Hǒpital Beaujon, 92118 Clichy, France
    • Service d'Hépatologie, Hǒpital Beaujon, 92118 Clichy, France
    Search for more papers by this author
  • Eric Bismuth,

    1. Service d'Hépatologie and Unité de Recherches de Physiopathologie Hépatique (INSERM), Hǒpital Beaujon, 92118 Clichy, France
    Search for more papers by this author
  • Michèle Martinot-Peignoux,

    1. Service d'Hépatologie and Unité de Recherches de Physiopathologie Hépatique (INSERM), Hǒpital Beaujon, 92118 Clichy, France
    Search for more papers by this author
  • Nathalie Boyer,

    1. Service d'Hépatologie and Unité de Recherches de Physiopathologie Hépatique (INSERM), Hǒpital Beaujon, 92118 Clichy, France
    Search for more papers by this author
  • Claude Degott,

    1. Service d'Hépatologie and Unité de Recherches de Physiopathologie Hépatique (INSERM), Hǒpital Beaujon, 92118 Clichy, France
    Search for more papers by this author
  • Serge Erlinger,

    1. Service d'Hépatologie and Unité de Recherches de Physiopathologie Hépatique (INSERM), Hǒpital Beaujon, 92118 Clichy, France
    Search for more papers by this author
  • Jean-Pierre Benhamou

    1. Service d'Hépatologie and Unité de Recherches de Physiopathologie Hépatique (INSERM), Hǒpital Beaujon, 92118 Clichy, France
    Search for more papers by this author

Abstract

The objective was to determine the proportion of patients with chronic hepatitis B in whom hepatitis B virus DNA is demonstrated by polymerase chain reaction after HBeAg to anti-HBe or HBsAg to anti-HBs spontaneous or therapeutically induced seroconversion.

Polymerase chain reaction was performed on serum 6 and 12 mo after HBeAg to anti-HBe seroconversion in 12 patients and 2, 6 and 12 mo after HBsAg to anti-HBs seroconversion in 13 patients. Polymerase chain reaction was performed on liver tissue after HBeAg to anti-HBe seroconversion in five patients and after HBsAg to anti-HBs seroconversion in one patient.

Serum HBV DNA was demonstrated by polymerase chain reaction in 83% of patients 6 or 12 mo after HBeAg to anti-HBe seroconversion and in 58%, 31% and 15% of patients at 2, 6 and 12 mo, respectively, after HEsAg to anti-HBs seroconversion. Liver HBV DNA was demonstrated by polymerase chain reaction in all patients tested.

Our results show that (a) a reduced level of hepatitis B virus replication persists in most of the patients after HBeAg to anti-HBe seroconversion and might be predictive of reactivation, and (b) in contrast, hepatitis B virus replication progressively disappears in most of the patients after HBsAg to anti-HBs seroconversion. (HEPATOLOGY 1992;15:32–36).

Ancillary